The field of TILs in BC is poised for several promising research directions: Biomarker Development: Future studies should focus on identifying robust biomarkers that can predict patient responses to immunotherapy, particularly in TNBC and HER2-positive subtypes. The gene discussed is ERBB2; the disease is breast cancer.